Comparison of ALA-PDT and CO2 laser treatment of low-grade vaginal intraepithelial neoplasia with high-risk HPV infection: A non-randomized controlled pilot study

Lili Wang,Xiaoli Liu,Junhua Zhang,Huamin Li,Xia Wang,Yuye Fu,Hongli Liu,Ying Xu,Lihua Meng,Baoxia Cui,Youzhong Zhang,Lin Jia
DOI: https://doi.org/10.1016/j.pdpdt.2023.103695
IF: 3.577
2023-07-08
Photodiagnosis and Photodynamic Therapy
Abstract:Objective To evaluate the efficacy and safety of 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) and CO 2 laser therapy of low-grade vaginal intraepithelial neoplasia (VAIN1) combined with high-risk human papillomavirus (hr-HPV) infection. Methods A total of 163 patients with VAIN1 and hr-HPV infection were divided into PDT Group (n = 83) and CO 2 laser Group (n = 80). The PDT Group received six times of ALA-PDT treatments and the CO 2 laser Group received once CO 2 laser treatment. HPV types, cytology, colposcopy, and pathological examinations were carried out before and after treatment. The differences in HPV clearance rate, VAIN1 regression rate, and adverse reactions between the two groups were analyzed during 6-month follow-up. Results The overall HPV clearance rate of the PDT Group was significantly higher than that of the CO 2 laser Group (65.06% vs 38.75%, P = 0.0008) although similar result was obtained for 16/18-related HPV infection patients (54.55% vs 43.48%, P = 0.4578). The VAIN1 regression rate of the PDT Group was significantly higher than that of the CO 2 laser Group (95.18% vs 83.75%, P = 0.0170). In patients ≥ 50 years old, ALA-PDT showed better HPV clearance rate and VAIN1 regression rate than CO 2 laser therapy ( P < 0.05). The adverse reactions in the PDT Group were significantly lower than that in the CO 2 laser Group ( P > 0.05). Conclusions The efficacy of ALA-PDT appears better than CO 2 laser for VAIN1 patients. However, the long-term effect of ALA-PDT for VAIN1 still needs to be explored. As a non-invasive treatment, ALA-PDT is a highly effective therapeutic procedure for VAIN1 with hr-HPV infection.
oncology
What problem does this paper attempt to address?